A new recombinant factor VIII: from genetics to clinical use

References

• Orlova NA Kovnir SV Vorobiev II Gabibov AG Vorobiev AI Blood clotting factor VIII: from evolution to therapy Acta Naturae 2013 5 2 19 39 23819034
   PubMed Web of Science ®Google Scholar
• Fay PJ Activation of factor VIII and mechanisms of cofactor action Blood Rev 2004 18 1 1 15 14684146
   PubMed Web of Science ®Google Scholar
• Sichler K Kopetzki E Huber R Bode W Hopfner KP Brandstetter H Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop J Biol Chem 2003 278 6 4121 4126 12444082
   PubMed Web of Science ®Google Scholar
• Shapiro AD Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A Vasc Health Risk Manag 2007 3 5 555 565 18078007
   PubMedGoogle Scholar
• NovoEight (antihemophilic factor [recombinant], prescribing information) Novo Nordisk Bagsværd, Denmark 2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002719/WC500157553.pdf Accessed June 30, 2014
   Google Scholar
• Franchini M Mannucci PM Hemophilia A in the third millennium Blood Rev 2013 27 4 179 184 23815950
   PubMed Web of Science ®Google Scholar
• Haddley K Turoctocog alfa for the treatment of hemophilia A Drugs Today (Barc) 2014 50 2 121 131 24619589
   PubMed Web of Science ®Google Scholar
• Lentz SR Seremetis S Staber J Kulkarni R Turoctocog alfa and drug development for hemophilia A Expert Opin Orphan Drugs 2014 2 4 419 431
   Web of Science ®Google Scholar
• Brooker M Registry of clotting factor concentrates 9th ed Montréal, QC, Canada World Federation of Hemophilia 2012 Available from: http://www1.wfh.org/publication/files/pdf-1227.pdf Accessed October 24, 2014
   Google Scholar
• Recombinate (antihemophilic factor [recombinant], prescribing information) Deerfield, IL, USA Baxter Healthcare Corporation 2010 Available from: http://www.baxter.com/downloads/healthcare_professionals/products/recombinate_pi_5ml.pdf Accessed June 30, 2014
   Google Scholar
• Kogenate FS (antihemophilic factor [recombinant], prescribing information) Berlin, Germany Bayer Schering Pharma AG 2006 Available from: http://www.abopharmaceuticals.com/ProductSheets/KogenateFS.pdf Accessed June 30, 2014
   Google Scholar
• Helixate FS (antihemophilic factor [recombinant], prescribing information) Kankakee, IL, USA CSL Behring 2013 Available from: http://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf Accessed June 30, 2014
   Google Scholar
• ReFacto (antihemophilic factor [recombinant], prescribing information) Madison, NJ, USA Wyeth Pharmaceuticals Inc 2005 Available from: http://www.abopharmaceuticals.com/ProductSheets/Refacto.pdf Accessed June 30, 2014
   Google Scholar
• Advate [antihemophilic factor (recombinant)] [prescribing information] Deerfield, IL, USA Baxter Healthcare Corporation 2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000520/WC500022467.pdf Accessed June 30, 2014
   Google Scholar
• Refacto AF (antihemophilic factor [recombinant], prescribing information) New York, NY, USA Pfizer 2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000232/WC500049008.pdf Accessed June 30, 2014
   Google Scholar
• Pipe SW Functional roles of the factor VIII B domain Haemophilia 2009 15 6 1187 1196 19473417
   PubMed Web of Science ®Google Scholar
• Grushin K Miller J Dalm D Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII Haemophilia 2014 20 5 723 731 24750465
   PubMed Web of Science ®Google Scholar
• Gitschier J Wood WI Goralka TM Characterization of the human factor VIII gene Nature 1984 312 5992 326 330 6438525
   PubMed Web of Science ®Google Scholar
• Solá RJ Griebenow K Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy Bio Drugs 2010 24 1 9 21
   Google Scholar
• Hollestelle MJ Thinnes T Crain K Tissue distribution of factor VIII gene expression in vivo – a closer look Thromb Haemost 2001 86 3 855 861 11583319
   PubMed Web of Science ®Google Scholar
• Shahani T Covens K Lavend’homme R Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII J Thromb Haemost 2014 12 1 36 42 24118899
   PubMed Web of Science ®Google Scholar
• Sandberg H Almstedt A Brandt J Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ Thromb Haemost 2001 85 1 93 100 11204595
   PubMed Web of Science ®Google Scholar
• Recht M Nemes L Matysiak M Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII Haemophilia 2009 15 4 869 880 19473411
   PubMed Web of Science ®Google Scholar
• Pittman DD Wang JH Kaufman RJ Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII Biochemistry 1992 31 13 3315 33325 1554716
   PubMed Web of Science ®Google Scholar
• Niehrs C Huttner WB Purification and characterization of tyrosylprotein sulfotransferase EMBO J 1990 9 1 35 42 2295314
   PubMed Web of Science ®Google Scholar
• Michnick DA Pittman DD Wise RJ Kaufman RJ Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage J Biol Chem 1994 269 31 20095 20102 8051097
   PubMed Web of Science ®Google Scholar
• Kaufman RJ Post-translational modifications required for coagulation factor secretion and function Thromb Haemost 1998 79 6 1068 1079 9657426
   PubMed Web of Science ®Google Scholar
• Gilbert GE Drinkwater D Barter S Clouse SB Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. Studies with model membranes supported by glass microspheres (lipospheres) J Biol Chem 1992 267 22 15861 15868 1639816
   PubMed Web of Science ®Google Scholar
• Fay PJ Coumans JV Walker FJ von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation J Biol Chem 1991 266 4 2172 2177 1846615
   PubMed Web of Science ®Google Scholar
• Nogami K Shima M Nishiya K A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation Blood 2002 99 11 3993 3998 12010799
   PubMed Web of Science ®Google Scholar
• Hay CR Factor VIII inhibitors in mild and moderate-severity haemophilia A Haemophilia 1998 4 4 558 563 9873794
   PubMed Web of Science ®Google Scholar
• Dasgupta S Repessé Y Bayry J VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors Blood 2007 109 2 610 612 16985172
   PubMed Web of Science ®Google Scholar
• Gringeri A Ofosu FA Grancha S Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010 Haemophilia 2012 18 3 469 475 21943193
   PubMed Web of Science ®Google Scholar
• Lin Y Yang X Chevrier MC Relationships between factor VIII: Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates Haemophilia 2004 10 5 459 469 15357771
   PubMed Web of Science ®Google Scholar
• Kannicht C Ramström M Kohla G Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII Thromb Res 2013 131 1 78 88 23058466
   PubMed Web of Science ®Google Scholar
• Grancha S Navajas R Marañón C Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates Haemophilia 2011 17 4 709 710 21299741
   PubMed Web of Science ®Google Scholar
• Chi EY Krishnan S Kendrick BS Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony stimulating factor Protein Sci 2003 12 5 903 913 12717013
   PubMed Web of Science ®Google Scholar
• Kessler CM Iorio A The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters Haemophilia 2013 19 3 351 354 23577743
   PubMed Web of Science ®Google Scholar
• Pahl S Pavlova A Driesen J In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile Haemophilia 2013 19 3 392 398 23252674
   PubMed Web of Science ®Google Scholar
• Kosloski MP Miclea RD Balu-Iyer SV Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII AAPS J 2009 11 3 424 431 19499345
   PubMed Web of Science ®Google Scholar
• Lenting PJ Pegon JN Christophe OD Denis CV Factor VIII and von Willebrand factor – too sweet for their own good Haemophilia 2010 16 Suppl 5 194 199 20590881
   PubMed Web of Science ®Google Scholar
• Schilow WF Schoerner-Burkhardt E Seitz R Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards Thromb Haemost 2004 92 2 427 428 15269842
   PubMed Web of Science ®Google Scholar
• Svensson LA Thim L Olsen OH Nicolaisen EM Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties Biol Chem 2013 394 6 761 765 23435097
   PubMed Web of Science ®Google Scholar
• Gringeri A Lambert T Street A Aledort L on behalf of the Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012 18 5 722 728 22639786
   PubMed Web of Science ®Google Scholar
• Peyvandi F Garagiola I Seregni S Future of coagulation factor replacement therapy J Thromb Haemost 2013 11 Suppl 1 84 98 23809113
   PubMed Web of Science ®Google Scholar
• Dimichele DM Blanchette V Berntorp E Clinical trial design in haemophilia Haemophilia 2012 18 Suppl 4 18 23 22726077
   PubMed Web of Science ®Google Scholar
• Makris M Calizzani G Fischer K EUHASS: The European Haemophilia Safety Surveillance System Thromb Res 2011 127 Suppl 2 S22 S25 21193110
   PubMed Web of Science ®Google Scholar
• Wight J Paisley S The epidemiology of inhibitors in haemophilia A: a systematic review Haemophilia 2003 9 4 418 435 12828678
   PubMed Web of Science ®Google Scholar
• Teitel JM Sholzberg M Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies Blood Rev 2013 27 2 103 109 23452718
   PubMed Web of Science ®Google Scholar
• Coppola A Di Minno MN Santagostino E Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches Br J Haematol 2010 150 5 515 528 20573153
   PubMed Web of Science ®Google Scholar
• Ettingshausen CE Kreuz W The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Haemophilia 2013 19 Suppl 1 12 17 23278995
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013 19 Suppl 1 2 7 23278993
   PubMed Web of Science ®Google Scholar
• Iorio A Halimeh S Holzhauer S Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review J Thromb Haemost 2010 8 6 1256 1265 20345722
   PubMed Web of Science ®Google Scholar
• Franchini M Coppola A Rocino A Italian Association of Hemophilia Centers (AICE) Working Group Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update Semin Thromb Hemost 2013 39 7 752 766 24022806
   PubMed Web of Science ®Google Scholar
• Gouw SC van der Bom JG Ljung R PedNet and RODIN Study Group Factor VIII products and inhibitor development in severe hemophilia A N Engl J Med 2013 368 3 231 239 23323899
   PubMed Web of Science ®Google Scholar
• Aledort LM Navickis RJ Wilkes MM Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies J Thromb Haemost 2011 9 11 2180 2192 21848690
   PubMed Web of Science ®Google Scholar
• Xi M Makris M Marcucci M Santagostino E Mannucci PM Iorio A Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression J Thromb Haemost 2013 11 9 1655 1662 23802542
   PubMed Web of Science ®Google Scholar
• Thim L Vandahl B Karlsson J Purification and characterization of a new recombinant factor VIII (N8) Haemophilia 2010 16 2 349 359 19906157
   PubMed Web of Science ®Google Scholar
• Gagnon P Cheung CW Lepin EJ Minibodies and multimodal chromatography methods: a convergence of challenge and opportunity Bioprocess Int 2010 8 2 26 35 21984873
   PubMedGoogle Scholar
• Lenting PJ van Mourik JA Mertens K The life cycle of coagulation factor VIII in view of its structure and function Blood 1998 92 11 3983 3996 9834200
   PubMed Web of Science ®Google Scholar
• Lind P Larsson K Spira J Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization Eur J Biochem 1995 232 1 19 27 7556150
   PubMedGoogle Scholar
• Medzihradszky KF Characterization of protein N-glycosylation Methods Enzymol 2005 405 116 138 16413313
   PubMed Web of Science ®Google Scholar
• Peter-Katalinic J Methods in enzymology: O-glycosylation of proteins Methods Enzymol 2005 405 139 171 16413314
   PubMed Web of Science ®Google Scholar
• Mazsaroff I Yu W Kelley BD Vath JE Quantitative comparison of global carbohydrate structures of glycoproteins using LC-MS and in-source fragmentation Anal Chem 1997 69 13 2517 2524 9212710
   PubMed Web of Science ®Google Scholar
• Leyte A van Schijndel HB Niehrs C Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor J Biol Chem 1991 266 2 740 746 1898735
   PubMed Web of Science ®Google Scholar
• Nielsen PF Bak S Vandahl B Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells Haemophilia 2012 18 5 e397 e398 22681385
   PubMed Web of Science ®Google Scholar
• Martinowitz U Bjerre J Brand B Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A Haemophilia 2011 17 6 854 859 21443634
   PubMed Web of Science ®Google Scholar
• Viuff D Barrowcliffe T Saugstrup T Ezban M Lillicrap D International comparative field study of N8 evaluating factor VIII assay performance Haemophilia 2011 17 4 695 702 21426445
   PubMed Web of Science ®Google Scholar
• Lentz SR Misgav M Ozelo M Results from a large multinational clinical trial (Guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy Haemophilia 2013 19 5 691 697 23647704
   PubMed Web of Science ®Google Scholar
• Kulkarni R Karim FA Glamocanin S Results from a large multinational clinical trial (Guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics Haemophilia 2013 19 5 698 705 23651313
   PubMed Web of Science ®Google Scholar
• Laguna P Vdovin V Rageliene L Abad-Franch L Lindblom A Overview of a global clinical trial programme with turoctocog alfa, a new recombinant factor VIII: the Guardian™ programme Presented at the XXIV International Society on Thrombosis and Haemostasis Congress Amsterdam, The Netherlands June 29 to July 4, 2013
   Google Scholar
• Ozelo M Misgav M Abdulkarim F Reductions in annualized bleeding rates over time with turoctocog alfa prophylaxis: 3-year interim results of the Guardian™ 2 extension trial Haemophilia 2014 20 Suppl 3 84
   Google Scholar